135 related articles for article (PubMed ID: 36598701)
1. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.
Li D; Shi Z; Liu X; Jin S; Chen P; Zhang Y; Chen G; Fan X; Yang J; Lin H
Hepatol Int; 2023 Feb; 17(1):112-130. PubMed ID: 36598701
[TBL] [Abstract][Full Text] [Related]
2. Cuproptosis-related molecular classification and gene signature of hepatocellular carcinoma and experimental verification.
Chen Z; Du D; Li J; Zhang W; Shao J
Transl Cancer Res; 2024 Mar; 13(3):1268-1289. PubMed ID: 38617510
[TBL] [Abstract][Full Text] [Related]
3. Cuproptosis-associated genes (CAGs) contribute to the prognosis prediction and potential therapeutic targets in hepatocellular carcinoma.
Shi X; Shi D; Yin Y; Wu Y; Chen W; Yu Y; Wang X
Cell Signal; 2024 May; 117():111072. PubMed ID: 38307306
[TBL] [Abstract][Full Text] [Related]
4. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
Wei M; Lu L; Luo Z; Ma J; Wang J
BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
[TBL] [Abstract][Full Text] [Related]
5. Exploring the Role of DNA Methylation Located in Cuproptosis-Related Genes: Implications for Prognosis and Immune Landscape in Hepatocellular Carcinoma.
Zhu R; Wang X; Sun F; Zhu L; Guo W
Front Biosci (Landmark Ed); 2024 Mar; 29(3):123. PubMed ID: 38538282
[TBL] [Abstract][Full Text] [Related]
6. Cuproptosis-related molecular patterns and gene (ATP7A) in hepatocellular carcinoma and their relationships with tumor immune microenvironment and clinical features.
Li S; Weng J; Xiao C; Lu J; Cao W; Song F; He Z; Zhang P; Zhu Z; Xu J
Cancer Rep (Hoboken); 2023 Dec; 6(12):e1904. PubMed ID: 37885090
[TBL] [Abstract][Full Text] [Related]
7. The cell death-related genes machine learning model for precise therapy and clinical drug selection in hepatocellular carcinoma.
Du M; Qu Y; Qin L; Zheng J; Sun W
J Cell Mol Med; 2024 Apr; 28(7):e18168. PubMed ID: 38494848
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 and Immune Infiltration of m
Lin Y; Yao Y; Wang Y; Wang L; Cui H
Biomed Res Int; 2021; 2021():5516100. PubMed ID: 34055974
[TBL] [Abstract][Full Text] [Related]
9. Development and Validation of the novel Cuproptosis- and Immune-related Signature for Predicting Prognosis in Hepatocellular Carcinoma.
Zhang Y; Sui P; Zhong C; Liu J
J Cancer; 2024; 15(8):2260-2275. PubMed ID: 38495502
[No Abstract] [Full Text] [Related]
10. A cuproptosis-related signature predicts prognosis and indicates cross-talk with immunocyte in ovarian cancer.
Yang B; Yang J; Zhang K
Discov Oncol; 2024 May; 15(1):141. PubMed ID: 38696071
[TBL] [Abstract][Full Text] [Related]
11. Integration of single-cell and bulk RNA-sequencing to analyze the heterogeneity of hepatocellular carcinoma and establish a prognostic model.
Mu Y; Zheng D; Peng Q; Wang X; Zhang Y; Yin Y; Wang E; Ye F; Wang J
Cancer Rep (Hoboken); 2024 Jan; 7(1):e1935. PubMed ID: 37994394
[TBL] [Abstract][Full Text] [Related]
12. Cuproptosis as the new kryptonite of cancer: a copper-dependent novel cell death mechanism with promising implications for the treatment of hepatocellular carcinoma.
Ozkan E; Bakar-Ates F
J Cancer Res Clin Oncol; 2023 Dec; 149(19):17663-17670. PubMed ID: 37843555
[TBL] [Abstract][Full Text] [Related]
13. Comprehending the cuproptosis and cancer-immunity cycle network: delving into the immune landscape and its predictive role in breast cancer immunotherapy responses and clinical endpoints.
Liu X; Xu F; Zhao K; Liu Y; Ye G; Zhang X; Qu Y
Front Immunol; 2024; 15():1344023. PubMed ID: 38312844
[TBL] [Abstract][Full Text] [Related]
14. Research progress in cuproptosis in liver cancer.
Chen L; Liu D; Tan Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Sept 28; 48(9):1368-1376. PubMed ID: 38044648
[TBL] [Abstract][Full Text] [Related]
15. Investigation of cuproptosis regulator-mediated modification patterns and SLC30A7 function in GBM.
Yu W; Gui S; Xie J; Peng L; Xiao J; Luo H; Tao Z; Cheng Z
Aging (Albany NY); 2024 Feb; 16(4):3554-3582. PubMed ID: 38393693
[TBL] [Abstract][Full Text] [Related]
16. Construction of an Immunogenic Cell Death-Related Gene Signature and Genetic Subtypes for Predicting Prognosis, Immune Microenvironments, and Drug Sensitivity in Hepatocellular Carcinoma.
Li S; Zhang T; Sun X; Li X
J Inflamm Res; 2024; 17():2427-2444. PubMed ID: 38681068
[TBL] [Abstract][Full Text] [Related]
17. Identification of a prognostic cuproptosis-related signature in hepatocellular carcinoma.
Chen Y; Tang L; Huang W; Abisola FH; Zhang Y; Zhang G; Yao L
Biol Direct; 2023 Feb; 18(1):4. PubMed ID: 36750831
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
Front Immunol; 2022; 13():991604. PubMed ID: 36685508
[TBL] [Abstract][Full Text] [Related]
19. Cuproptosis: mechanisms and links with cancers.
Xie J; Yang Y; Gao Y; He J
Mol Cancer; 2023 Mar; 22(1):46. PubMed ID: 36882769
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
